Treatment of cannabis use disorder
- David A Gorelick, MD, PhD
David A Gorelick, MD, PhD
- Professor of Psychiatry
- University of Maryland School of Medicine
Cannabis (also called marijuana) is the most commonly used illegal psychoactive substance worldwide . Its psychoactive properties are primarily due to one cannabinoid: delta-9-tetrahydrocannabinol (THC); THC concentration is commonly used as a measure of cannabis potency .
Cannabis use disorder develops in approximately 10 percent of regular cannabis users and may be associated with cognitive impairment, poor school or work performance, and psychiatric comorbidity such as mood disorders and psychosis.
The treatment of cannabis use disorder is reviewed here. Clinical manifestations, course, assessment, and diagnosis of cannabis use disorder in adults are reviewed separately. The epidemiology and health consequences of cannabis use and cannabis use disorder are also reviewed separately. The pathogenesis and pharmacology of cannabis use disorder in adults are also reviewed separately. Acute intoxication, from cannabis and synthetic cannabinoids, and cannabis withdrawal are also reviewed separately. (See "Cannabis use and disorder: Clinical manifestations, course, assessment, and diagnosis" and "Cannabis use and disorder: Epidemiology, comorbidity, health consequences, and medico-legal status" and "Cannabis use and disorder: Pathogenesis and pharmacology" and "Cannabis (marijuana): Acute intoxication" and "Synthetic cannabinoids: Acute intoxication" and "Cannabis withdrawal: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis" and "Treatment of cannabis withdrawal".)
APPROACH TO TREATMENT
General principles — Treatment for cannabis use disorder usually occurs on an outpatient basis, but residential treatment may be required for patients who cannot remain abstinent in an ambulatory setting or those with multiple concurrent substance use disorders. Treatment may occur in an inpatient hospital setting if the patient is psychotic, suicidal, severely depressed or agitated, or requires hospitalization because of another concurrent psychiatric disorder.
The patient's social network, especially family, should be involved in treatment to the extent possible (and agreed to by the patient, if a legally competent adult), in order to provide additional history and therapeutic support and to help monitor the patient's progress and adherence to treatment.To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- United Nations Office on Drugs and Crime, World Drug Report 2016, Vienna 2016.
- Swift W, Wong A, Li KM, et al. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One 2013; 8:e70052.
- Levin FR, Mariani JJ, Brooks DJ, et al. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011; 116:142.
- Goldstein RB, Chou SP, Smith SM, et al. Nosologic Comparisons of DSM-IV and DSM-5 Alcohol and Drug Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. J Stud Alcohol Drugs 2015; 76:378.
- Mewton L, Slade T, Teesson M. An evaluation of the proposed DSM-5 cannabis use disorder criteria using Australian national survey data. J Stud Alcohol Drugs 2013; 74:614.
- Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2014; :CD008940.
- Gates PJ, Sabioni P, Copeland J, et al. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev 2016; :CD005336.
- Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol 2000; 68:898.
- Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat 2001; 21:55.
- Stephens RS, Roffman RA, Fearer SA, et al. The Marijuana Check-up: promoting change in ambivalent marijuana users. Addiction 2007; 102:947.
- Kadden RM, Litt MD, Kabela-Cormier E, Petry NM. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 2007; 32:1220.
- Carroll KM, Nich C, Lapaglia DM, et al. Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less. Addiction 2012; 107:1650.
- Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 2006; 74:307.
- Fischer B, Dawe M, McGuire F, et al. Feasibility and impact of brief interventions for frequent cannabis users in Canada. J Subst Abuse Treat 2013; 44:132.
- Edwards J, Elkins K, Hinton M, et al. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand 2006; 114:109.
- Harris SK, Louis-Jacques J, Knight JR. Screening and brief intervention for alcohol and other abuse. Adolesc Med State Art Rev 2014; 25:126.
- Bogenschutz MP, Donovan DM, Mandler RN, et al. Brief intervention for patients with problematic drug use presenting in emergency departments: a randomized clinical trial. JAMA Intern Med 2014; 174:1736.
- Roy-Byrne P, Bumgardner K, Krupski A, et al. Brief intervention for problem drug use in safety-net primary care settings: a randomized clinical trial. JAMA 2014; 312:492.
- Saitz R, Palfai TP, Cheng DM, et al. Screening and brief intervention for drug use in primary care: the ASPIRE randomized clinical trial. JAMA 2014; 312:502.
- Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 2004; 72:455.
- Stanger C, Budney AJ, Kamon JL, Thostensen J. A randomized trial of contingency management for adolescent marijuana abuse and dependence. Drug Alcohol Depend 2009; 105:240.
- Sherman BJ, McRae-Clark AL. Treatment of Cannabis Use Disorder: Current Science and Future Outlook. Pharmacotherapy 2016; 36:511.
- Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012; 169:805.
- Gray KM, Sonne SC, McClure EA, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend 2017; 177:249.
- Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012; 37:1689.
- Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004; 29:158.
- Haney M, Hart CL, Vosburg SK, et al. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2008; 197:157.
- APPROACH TO TREATMENT
- General principles
- Specific interventions
- PSYCHOSOCIAL INTERVENTIONS
- Cognitive-behavioral therapy
- Motivational interviewing/motivational enhancement
- Contingency management
- Drug or addiction counseling
- Screening and brief intervention
- Mutual help groups
- Combined interventions
- - Efficacy
- - Side effects
- - Efficacy
- - Side effects
- - Administration
- Cannabinoid agonists
- SOCIETY GUIDELINE LINKS
- SUMMARY AND RECOMMENDATIONS